Cystic Fibrosis Global Clinical Trials Review, H2, 2016 - GlobalData

Cystic Fibrosis Global Clinical Trials Review, H2, 2016

Cystic Fibrosis Global Clinical Trials Review, H2, 2016 - GlobalData
Cystic Fibrosis Global Clinical Trials Review, H2, 2016
Published Aug 31, 2016
456 pages — Published Aug 31, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's clinical trial report, Cystic Fibrosis Global Clinical Trials Review, H2, 2016' provides an overview of Cystic Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Cystic Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  
Source:
Document ID
GDHC3675CTIDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Report Guidance51
Clinical Trials by Region68
  Clinical Trials and Average Enrollment by Country72
    Top Five Countries Contributing to Clinical Trials in Asia-Pacific91
    Top Five Countries Contributing to Clinical Trials in Europe101
    Top Countries Contributing to Clinical Trials in North America111
    Top Countries Contributing to Clinical Trials in Middle East and Africa121
    Top Five Countries Contributing to Clinical Trials in Central and South America131
Clinical Trials by G7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials141
Clinical Trials by Phase in G7 Countries151
Clinical Trials in G7 Countries by Trial Status161
Clinical Trials by E7 Countries: Proportion of Cystic Fibrosis to Respiratory Clinical Trials171
Clinical Trials by Phase in E7 Countries181
Clinical Trials in E7 Countries by Trial Status191
Clinical Trials by Phase202
  In Progress Trials by Phase211
Clinical Trials by Trial Status221
Clinical Trials by End Point Status231
Subjects Recruited Over a Period of Time241
Clinical Trials by Sponsor Type251
Prominent Sponsors263
  Top Companies Participating in Cystic Fibrosis Therapeutics Clinical Trials272
Prominent Drugs291
Latest Clinical Trials News on Cystic Fibrosis308
  Aug 16, 2016: Anthera Pharmaceuticals Announces Positive DSMB Review in Phase 3 SOLUTION Study of Sollpura301
  Aug 15, 2016: Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis301
  Jul 15, 2016: Pharmaxis Completes Recruitment of Pivotol Bronchitol Cystic Fibrosis Clinical Trial for US Market311
  Jul 07, 2016: Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis311
  Jul 07, 2016: Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis321
  Jun 21, 2016: ProQR to Release Topline Data from Proof of Concept Study of QR-010 in Cystic Fibrosis Patients at NACFC321
  Jun 10, 2016: Vertex Announces Presentation of Data for KALYDECO (ivacaftor) at European Cystic Fibrosis Society Conference331
  Jun 10, 2016: Vertex Announces Presentation of Data for ORKAMBI (lumacaftor/ivacaftor) at European Cystic Fibrosis Society Conference341
  Jun 10, 2016: Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR at the 39th European Cystic Fibrosis Conference351
  Jun 10, 2016: New Analyses from Phase 3 Study 009 of Translarna (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference361
  Jun 10, 2016: Concert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference361
  Jun 07, 2016: Raptor Pharmaceutical to Present Data on QUINSAIR at European Cystic Fibrosis Conference371
Clinical Trial Profile Snapshots38415
Appendix4533
  Abbreviations4531
  Definitions4531
  Research Methodology4541
  Secondary Research4541
  About GlobalData4551
  Contact Us4551
  Disclaimer4551
Source4561

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Cystic Fibrosis Global Clinical Trials Review, H2, 2016" Aug 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Cystic-Fibrosis-Global-Clinical-Trials-Review-H2-2016-2085-23596>
  
APA:
GlobalData. (2016). Cystic Fibrosis Global Clinical Trials Review, H2, 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Cystic-Fibrosis-Global-Clinical-Trials-Review-H2-2016-2085-23596>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.